Corcept Therapeutics Incorporated (LON:0I3Q)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 5.63B |
| Revenue (ttm) | 530.53M |
| Net Income (ttm) | 102.56M |
| Shares Out | n/a |
| EPS (ttm) | 0.88 |
| PE Ratio | 54.90 |
| Forward PE | 43.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,912 |
| Average Volume | 453 |
| Open | 72.00 |
| Previous Close | 71.78 |
| Day's Range | 66.67 - 72.00 |
| 52-Week Range | 29.64 - 115.27 |
| Beta | n/a |
| RSI | 49.97 |
| Earnings Date | Jul 30, 2025 |
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t... [Read more]
Financial Performance
In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.
Financial numbers in USD Financial StatementsNews
Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
Applications of Relacorilant and Corcept's other cortisol modulators are not being valued by investors. Results from the Rosella clinical trials showcase the multifaceted applications of cortisol modu...
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
Treatment with a cortisol modulator significantly improves glucose control in patients with hypercortisolism and difficult-to-control diabetes, accompanied by reductions in body weight, waist circumfe...
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Insider Decision: Gary Charles Robb Offloads $225K Worth Of Corcept Therapeutics Stock
It was reported on June 18, that Gary Charles Robb , Chief Business Officer at Corcept Therapeutics (NASDAQ: CORT) executed a significant insider sell, according to an SEC filing. What Happened: Robb...
Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring
Corcept Therapeutics remains a strong buy, with recent stock weakness attributed to put options trading rather than fundamental issues. Management maintains aggressive 2025 and long-term revenue guida...
Major Update: LEONARD BAKER JR At Corcept Therapeutics Exercises Options, Realizing $0
Disclosed in a recent SEC filing on June 13, JR, Board Member at Corcept Therapeutics (NASDAQ: CORT), made a noteworthy transaction involving the exercise of company stock options. What Happened: Dis...
20 stocks you should avoid — no matter how well the market does
These hard-to-short stocks are likely to lose money, researchers found.
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today
Corcept Therapeutics (NASDAQ: CORT) has outperformed the market over the past 5 years by 26.38% on an annualized basis producing an average annual return of 40.21%. Currently, Corcept Therapeutics ha...
How Do Investors Really Feel About Corcept Therapeutics?
Corcept Therapeutics's (NYSE: CORT) short percent of float has fallen 25.63% since its last report. The company recently reported that it has 12.29 million shares sold short , which is 16.31% of all ...
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat serious endocrinolo...
Corcept Therapeutics Q1 2025 Earnings Preview
Corcept Therapeutics (CORT) to report Q1 earnings on May 5th. Analysts expect $0.14 EPS and $177.93M revenue (+21.2% Y/Y).
Earnings Scheduled For May 5, 2025
Companies Reporting Before The Bell • Recursion Pharmaceuticals (NASDAQ: RXRX) is likely to report quarterly loss at $0.52 per share on revenue of $18.08 million. • Freshpet (NASDAQ: FRPT) is estima...
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. Th...
Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today
Corcept Therapeutics (NASDAQ: CORT) has outperformed the market over the past 10 years by 18.46% on an annualized basis producing an average annual return of 28.66%. Currently, Corcept Therapeutics h...
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss
Despite a Q4 revenue miss, Corcept's 2025 revenue still grew 40% to $675 million, and management provided strong guidance for 2025 and beyond, projecting up to $5 billion in revenue. Corcept's potenti...
Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder
Corcept is transitioning from a single-product company to a multi-product, multi-market Platform Growth™ company, promising rapid revenue and earnings growth. Relacorilant's success in platinum-resist...
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept Therapeutics Unusual Options Activity For April 01
Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics (NASDAQ: CORT). And retail traders should know. We noticed this today when the trades showed up on publicly ...